VAULT BIOVENTURES

Serial Number 97639433
606

Registration Progress

Application Filed
Oct 19, 2022
Under Examination
Feb 18, 2025
Approved for Publication
Dec 24, 2024
Published for Opposition
Dec 24, 2024
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: VAULT BIOVENTURES
Previous Owner: Vault Bioventures, Inc.
Classes: 005, 042

Trademark Image

VAULT BIOVENTURES

Basic Information

Serial Number
97639433
Filing Date
October 19, 2022
Published for Opposition
December 24, 2024
Abandonment Date
September 22, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Sep 22, 2025
Classes
005 042

Rights Holder

Vault Bioventures, Inc.

03
Address
12555 High Bluff Dr., Suite 300
San Diego, CA 92130

Ownership History

Vault Bioventures, Inc.

Original Applicant
03
San Diego, CA

Vault Bioventures, Inc.

Owner at Publication
03
San Diego, CA

Legal Representation

Attorney
Barry F. Soalt

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

39 events
Date Code Type Description Documents
Sep 22, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Sep 22, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Feb 18, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 24, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 24, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 18, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 26, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 26, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Nov 26, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Nov 26, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Nov 26, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Nov 7, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 7, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 7, 2024 ALIE A ASSIGNED TO LIE Loading...
Aug 16, 2024 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
May 3, 2024 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
May 3, 2024 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
May 3, 2024 CNSL R SUSPENSION LETTER WRITTEN Loading...
Apr 30, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 29, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 29, 2024 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Feb 5, 2024 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Feb 5, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Feb 5, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 5, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jan 30, 2024 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Jan 30, 2024 GNFR O FINAL REFUSAL E-MAILED Loading...
Jan 30, 2024 CNFR R FINAL REFUSAL WRITTEN Loading...
Dec 29, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 28, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 28, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 26, 2023 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Sep 26, 2023 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Jun 28, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 28, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 28, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 27, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 3, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 22, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical products for the treatment of viral and infectious diseases, allergies, diabetes, and for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood, weight, pregnancy and immune system related diseases and disorders, all for the purpose of integrating digital and biopharmaceutical therapeutics to increase health-span and life-span for all humanity
Class 042
Pharmaceutical product development services; Pharmaceutical research services

Classification

International Classes
005 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOVENTURES"